<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="471">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05155020</url>
  </required_header>
  <id_info>
    <org_study_id>AK120-201</org_study_id>
    <nct_id>NCT05155020</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter, phase II clinical study&#xD;
      to evaluate the efficacy and safety of AK120 in the treatment of subjects with&#xD;
      moderate-to-severe asthma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter, phase II clinical study.&#xD;
      The purpose of this study is to evaluate the efficacy and safety of AK120 in the treatment of&#xD;
      subjects with moderate-to-severe asthma and not adequately controlled with current stable&#xD;
      medium-to-high-dose inhaled glucocorticoids plus up to two additional controllers.Subjects&#xD;
      will be randomized to receive AK120 or placebo subcutaneous injection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pre-bronchodilator forced expiratory volume in 1 second (FEV1) from baseline at week 12.</measure>
    <time_frame>At week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of severe exacerbation events within 24 weeks.</measure>
    <time_frame>Baseline to Week24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of severe exacerbation events within 32 weeks.</measure>
    <time_frame>Baseline to Week32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pre-bronchodilator FEV1 from baseline to week 32.</measure>
    <time_frame>Baseline to Week32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in pre-bronchodilator FEV1 from baseline to week 32.</measure>
    <time_frame>Baseline to Week32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in post-bronchodilator FEV1 from baseline to week 32.</measure>
    <time_frame>Baseline to Week32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fractional exhaled nitric oxide (FeNO) from baseline to week 32.</measure>
    <time_frame>Baseline to Week32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in asthma control questionnaire (ACQ-5) scores from baseline to week 32.</measure>
    <time_frame>Baseline to Week32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in standardized version of the asthma quality of life (AQLQ-s) scores from baseline at week 12 and 24.</measure>
    <time_frame>at week 12,week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment: treatment-emergent adverse events (TEAE), serious adverse events (SAE) .</measure>
    <time_frame>Baseline to Week32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): AK120 concentration at different time points.</measure>
    <time_frame>Baseline to Week32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity assessment: number and percentage of subjects with detectable anti-AK120 antibody (ADA).</measure>
    <time_frame>Baseline to Week32</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>AK120 regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AK120 regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AK120 regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AK120</intervention_name>
    <description>AK120 regimen 1-subcutaneous injection every two weeks up to week 24, and follow up to week 32.</description>
    <arm_group_label>AK120 regimen 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AK120</intervention_name>
    <description>AK120 regimen 2(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.</description>
    <arm_group_label>AK120 regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AK120</intervention_name>
    <description>AK120 regimen 3(first dose doubling)-subcutaneous injection and then every two weeks up to week 24, and follow up to week 32.</description>
    <arm_group_label>AK120 regimen 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo subcutaneous injection every two weeks up to week 24, and follow up to week 32.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects aged ≥18 years old and ≤75 years old;&#xD;
&#xD;
          2. Asthma was diagnosed ≥ 12 months before screening, current stable treatment with&#xD;
             medium-to-high-dose inhaled glucocorticoids plus up to two additional controllers ≥ 3&#xD;
             months;&#xD;
&#xD;
          3. Blood eosinophil≥ 200 cells per microliter within 6 months before screening;&#xD;
&#xD;
          4. During the screening, 40% of the predicted normal value &lt; pre-bronchodilator FEV1 &lt;&#xD;
             80% of the predicted normal value, within 12 months before randomization, reversible&#xD;
             airflow restriction was recorded;&#xD;
&#xD;
          5. Asthma was inadequately controlled;&#xD;
&#xD;
          6. For women with childbearing potential, they are not pregnant or lactating, and the&#xD;
             subjects and their partners voluntarily take effective contraceptive measures judged&#xD;
             by the investigators during the treatment and at least 3 months after last dose.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with lung diseases other than asthma, which may affect the subject's health&#xD;
             or end point evaluation of the study;&#xD;
&#xD;
          2. Subjects had severe exacerbation events or systemic glucocorticoids usage within 1&#xD;
             month before randomization;&#xD;
&#xD;
          3. Respiratory tract infection and any serious infection within 1 month before&#xD;
             randomization;&#xD;
&#xD;
          4. Subjects with parasitic infection, active tuberculosis infection, Hepatitis B,&#xD;
             hepatitis C, human immunodeficiency virus (HIV) or syphilis positive confirmation&#xD;
             test;&#xD;
&#xD;
          5. Known or suspected history of immunosuppression;&#xD;
&#xD;
          6. History of malignant tumors;&#xD;
&#xD;
          7. A history of smoking: those who had quit smoking for ≤ 6 months before screening, or&#xD;
             smoking history &gt; 10 pack per year;&#xD;
&#xD;
          8. Previous treatment with interleukin-4 (IL-4) or interleukin-13 (IL-13) inhibitors, and&#xD;
             inadequate washout period of other biologic therapy;&#xD;
&#xD;
          9. Allergen immunotherapy within 3 months before randomization;&#xD;
&#xD;
         10. Progressive or uncontrolled other diseases or any other conditions or abnormal&#xD;
             laboratory tests for which the investigator assess that the subjects are not suitable&#xD;
             to enrol in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Miao Wang</last_name>
    <phone>+86 (0760) 8987 3999</phone>
    <email>global.trials@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Jingmei General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cangzhou People's Hospital</name>
      <address>
        <city>Cangzhou</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luoyang Central Hospital</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baogang Hospital, Inner Mongolia, China</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inner Mongolia People's Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial Prople's Hospita</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi Pingxiang People's Hospital</name>
      <address>
        <city>Pingxiang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jilin Province People's Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Zhejiang University School of Medicine,</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 1, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AK120</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

